Panagene Inc (046210) - Total Assets
Based on the latest financial reports, Panagene Inc (046210) holds total assets worth ₩101.91 Billion KRW (≈ $69.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Panagene Inc shareholders equity for net asset value and shareholders' equity analysis.
Panagene Inc - Total Assets Trend (2005–2024)
This chart illustrates how Panagene Inc's total assets have evolved over time, based on quarterly financial data.
Panagene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Panagene Inc's total assets of ₩101.91 Billion consist of 63.4% current assets and 36.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩35.91 Billion | 32.8% |
| Accounts Receivable | ₩3.81 Billion | 3.5% |
| Inventory | ₩3.98 Billion | 3.6% |
| Property, Plant & Equipment | ₩14.28 Billion | 13.0% |
| Intangible Assets | ₩2.92 Billion | 2.7% |
| Goodwill | ₩6.61 Billion | 6.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Panagene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 046210 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panagene Inc's current assets represent 63.4% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, up from 0.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is cash and equivalents at 32.8% of total assets.
Panagene Inc Competitors by Total Assets
Key competitors of Panagene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
Panagene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.46 | 18.91 |
| Quick Ratio | 2.04 | 2.33 | 15.70 |
| Cash Ratio | 0.00 | 0.24 | 0.00 |
| Working Capital | ₩27.01 Billion | ₩45.69 Billion | ₩17.59 Billion |
Panagene Inc - Advanced Valuation Insights
This section examines the relationship between Panagene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | ₩109.61 Billion |
| Market Capitalization | $46.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Panagene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Panagene Inc's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Panagene Inc (2005–2024)
The table below shows the annual total assets of Panagene Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩109.61 Billion ≈ $74.28 Million |
+20.57% |
| 2023-12-31 | ₩90.91 Billion ≈ $61.61 Million |
+162.20% |
| 2022-12-31 | ₩34.67 Billion ≈ $23.50 Million |
+8.66% |
| 2021-12-31 | ₩31.91 Billion ≈ $21.62 Million |
+17.18% |
| 2020-12-31 | ₩27.23 Billion ≈ $18.45 Million |
+24.99% |
| 2019-12-31 | ₩21.79 Billion ≈ $14.76 Million |
-9.51% |
| 2018-12-31 | ₩24.08 Billion ≈ $16.32 Million |
-13.69% |
| 2017-12-31 | ₩27.90 Billion ≈ $18.90 Million |
-15.52% |
| 2016-12-31 | ₩33.02 Billion ≈ $22.38 Million |
+28.78% |
| 2015-12-31 | ₩25.64 Billion ≈ $17.38 Million |
+0.53% |
| 2012-12-31 | ₩25.51 Billion ≈ $17.28 Million |
-39.88% |
| 2011-12-31 | ₩42.42 Billion ≈ $28.75 Million |
+10.73% |
| 2010-12-31 | ₩38.31 Billion ≈ $25.96 Million |
+16.47% |
| 2009-12-31 | ₩32.90 Billion ≈ $22.29 Million |
-34.57% |
| 2008-12-31 | ₩50.28 Billion ≈ $34.07 Million |
-0.79% |
| 2007-12-31 | ₩50.68 Billion ≈ $34.35 Million |
-13.62% |
| 2006-12-31 | ₩58.67 Billion ≈ $39.76 Million |
-7.48% |
| 2005-12-31 | ₩63.42 Billion ≈ $42.98 Million |
-- |
About Panagene Inc
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more